{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:46:29Z","timestamp":1794087989594,"version":"4.8.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["813528"],"award-info":[{"award-number":["813528"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials Advances"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.bioadv.2022.213125","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T02:11:13Z","timestamp":1663380673000},"page":"213125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy"],"prefix":"10.1016","volume":"141","author":[{"given":"Sara Lopes","family":"van den Broek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Shalgunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias M.","family":"Herth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioadv.2022.213125_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2021.119326","article-title":"Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases","volume":"274","author":"Anthony","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.bioadv.2022.213125_bb0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0015","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.7150\/thno.21254","article-title":"Current strategies for brain drug delivery","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.bioadv.2022.213125_bb0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioadv.2022.213125_bb0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11030-016-9715-6","article-title":"The role of multidrug resistance protein (MRP-1) as an active efflux transporter on blood\u2013brain barrier (BBB) permeability","volume":"21","author":"Lingineni","year":"2017","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioadv.2022.213125_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/acscombsci.6b00116","article-title":"Rationally designed peptides and peptidomimetics as inhibitors of amyloid-\u03b2 (A\u03b2) aggregation: potential therapeutics of Alzheimer's disease","volume":"19","author":"Goyal","year":"2017","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.bioadv.2022.213125_bb0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2009.07.028","article-title":"Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases","volume":"37","author":"Gabathuler","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bioadv.2022.213125_bb0040","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/mp400680d","article-title":"Strategies to deliver peptide drugs to the brain","volume":"11","author":"Lalatsa","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioadv.2022.213125_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1359-6446(00)01583-X","article-title":"Crossing the blood-brain barrier: are we getting it right?","volume":"6","author":"Pardridge","year":"2001","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioadv.2022.213125_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules26030627","article-title":"The pharmaceutical industry in 2020. An analysis of fda drug approvals from the perspective of molecules","volume":"26","author":"de la Torre","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioadv.2022.213125_bb0055","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1039\/C8MD90019A","article-title":"What are the drugs of the future?","volume":"9","author":"Ngo","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.bioadv.2022.213125_bb0060","series-title":"Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals","author":"Globerman","year":"2016"},{"key":"10.1016\/j.bioadv.2022.213125_bb0065","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1517\/14712598.4.8.1345","article-title":"Small molecules for small minds? The case for biologic pharmaceuticals","volume":"4","author":"Projan","year":"2004","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.bioadv.2022.213125_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2017.00086","article-title":"Increasing of blood-brain tumor barrier permeability through transcellular and paracellular pathways by microbubble-enhanced diagnostic ultrasound in a C6 glioma model","volume":"11","author":"Zhang","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bioadv.2022.213125_bb0075","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/acs.bioconjchem.5b00607","article-title":"Transforming nanomedicines from lab scale production to novel clinical modality","volume":"27","author":"Landesman-Milo","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioadv.2022.213125_bb0080","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2012.10.007","article-title":"Challenges and opportunities in the advancement of nanomedicines","volume":"164","author":"Wei","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2022.213125_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120807","article-title":"PLGA-based nanomedicines manufacturing: technologies overview and challenges in industrial scale-up","volume":"605","author":"Operti","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioadv.2022.213125_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12071868","article-title":"Development of antibody immuno-PET\/SPECT radiopharmaceuticals for imaging of oncological disorders\u2014an update","volume":"12","author":"Dewulf","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioadv.2022.213125_bb0095","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2014.57.8278","article-title":"Antibody positron emission tomography imaging in anticancer drug development","volume":"33","author":"Lamberts","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0100","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1021\/acschemneuro.0c00652","article-title":"Fluorine-18-labeled antibody ligands for PET imaging of amyloid-\u03b2 in brain","volume":"11","author":"Syv\u00e4nen","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioadv.2022.213125_bb0105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40259-017-0248-z","article-title":"Delivery of biologics across the blood-brain barrier with molecular trojan horse technology","volume":"31","author":"Pardridge","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.bioadv.2022.213125_bb0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.15171\/bi.2016.30","article-title":"Blood-brain barrier transport machineries and targeted therapy of brain diseases","volume":"6","author":"Barar","year":"2016","journal-title":"BioImpacts"},{"key":"10.1016\/j.bioadv.2022.213125_bb0115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s13238-017-0457-8","article-title":"Current progress in innovative engineered antibodies","volume":"9","author":"Strohl","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.bioadv.2022.213125_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph14020092","article-title":"Monoclonal antibodies as neurological therapeutics","volume":"14","author":"Gklinos","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioadv.2022.213125_bb0125","series-title":"Textbook of Drug Design and Discovery","first-page":"119","article-title":"In vivo imaging in drug discovery","author":"Kristensen","year":"2017"},{"key":"10.1016\/j.bioadv.2022.213125_bb0130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clpt.2006.05.008","article-title":"Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs","volume":"80","author":"Lappin","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bioadv.2022.213125_bb0135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2016.02.008","article-title":"New developments for antibody-drug conjugate-based therapeutic approaches","volume":"40","author":"de Goeij","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0140","doi-asserted-by":"crossref","first-page":"308","DOI":"10.7150\/thno.17155","article-title":"Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor","volume":"7","author":"Hultqvist","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.bioadv.2022.213125_bb0145","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1021\/ar200019c","article-title":"Theranostic nanomedicine","volume":"44","author":"Lammers","year":"2011","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bioadv.2022.213125_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/nbt1006-1211","article-title":"The emerging nanomedicine landscape","volume":"24","author":"Wagner","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0155","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1177\/0271678X20951995","article-title":"Regulation of blood\u2013brain barrier integrity by microglia in health and disease: a therapeutic opportunity","volume":"40","author":"Ronaldson","year":"2020","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bioadv.2022.213125_bb0160","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.tim.2012.03.009","article-title":"Viral disruption of the blood-brain barrier","volume":"20","author":"Spindler","year":"2012","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0165","first-page":"1","article-title":"Transcytosis to cross the blood brain barrier, new advancements and challenges","volume":"13","author":"Pulgar","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bioadv.2022.213125_bb0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bioadv.2022.213125_bb0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2015.11.032","article-title":"Revisiting nanoparticle technology for blood\u2013brain barrier transport: unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes","volume":"222","author":"Johnsen","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2022.213125_bb0180","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1161\/CIRCRESAHA.116.306534","article-title":"Protein interactions at endothelial junctions and signaling mechanisms regulating endothelial permeability","volume":"120","author":"Komarova","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.bioadv.2022.213125_bb0185","doi-asserted-by":"crossref","first-page":"E524","DOI":"10.1073\/pnas.1614336114","article-title":"Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis","volume":"114","author":"L\u00e9cuyer","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioadv.2022.213125_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","article-title":"The blood \u2013 brain barrier : an overview structure, regulation, and clinical implications","volume":"16","author":"Ballabh","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bioadv.2022.213125_bb0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte \u2013 endothelial interactions at the blood \u2013 brain barrier","volume":"7","author":"Abbott","year":"2006","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bioadv.2022.213125_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-8118-9-23","article-title":"Tight junctions at the blood brain barrier : physiological architecture and disease-associated dysregulation","volume":"9","author":"Luissint","year":"2012","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.bioadv.2022.213125_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23061289","article-title":"Strategies for enhancing the permeation of cns-active drugs through the blood-brain barrier: a review","volume":"23","author":"Zeiadeh","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bioadv.2022.213125_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12100937","article-title":"Brain delivery of single-domain antibodies: a focus on VHH and VNAR","volume":"12","author":"Pothin","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioadv.2022.213125_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12010062","article-title":"Antibodies for the treatment of brain metastases, a dream or a reality?","volume":"12","author":"Cavaco","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioadv.2022.213125_bb0220","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jconrel.2020.03.001","article-title":"Novel cyclic peptides facilitating transcellular blood-brain barrier transport of macromolecules in vitro and in vivo","volume":"321","author":"Yamaguchi","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2022.213125_bb0225","first-page":"1929","article-title":"O2 exchange between blood and brain tissues studied with 1802 indicator-dilution technique","volume":"58","author":"Grieb","year":"1985","journal-title":"J. Appl. Phys."},{"key":"10.1016\/j.bioadv.2022.213125_bb0230","series-title":"Blood \u2013 Brain Barrier Delivery","first-page":"54","volume":"12","author":"Pardridge","year":"2007"},{"key":"10.1016\/j.bioadv.2022.213125_bb0235","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1021\/acs.jmedchem.9b01220","article-title":"The blood-brain barrier (BBB) score","volume":"62","author":"Gupta","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioadv.2022.213125_bb0240","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s11095-013-1156-7","article-title":"Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases","volume":"30","author":"Bozda\u011f Pehlivan","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioadv.2022.213125_bb0245","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-018-0563-0","article-title":"Possible strategies to cross the blood\u2013brain barrier","volume":"44","author":"Bellettato","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.bioadv.2022.213125_bb0250","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","article-title":"Biodistribution of 89 Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer","volume":"87","author":"Dijkers","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bioadv.2022.213125_bb0255","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ctrv.2013.01.006","article-title":"A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer","volume":"39","author":"Larsen","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioadv.2022.213125_bb0260","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1471-4159.2009.06319.x","article-title":"The blood-brain barrier in neurodegenerative disease: a rhetorical perspective","volume":"111","author":"Carvey","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioadv.2022.213125_bb0265","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1111\/j.1460-9568.2005.04479.x","article-title":"Physiological characterization, localization and synaptic inputs of bursting and nonbursting neurons in the trigeminal principal sensory nucleus of the rat","volume":"22","author":"Athanassiadis","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bioadv.2022.213125_bb0270","doi-asserted-by":"crossref","first-page":"10919","DOI":"10.1039\/C7NR00305F","article-title":"A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin","volume":"9","author":"Prabhu","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.bioadv.2022.213125_bb0275","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neuropharm.2016.08.025","article-title":"Targeting blood-brain-barrier transcytosis \u2013 perspectives for drug delivery","volume":"120","author":"M\u00e4ger","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioadv.2022.213125_bb0280","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/17425247.2014.952627","article-title":"Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody","volume":"12","author":"Pardridge","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.bioadv.2022.213125_bb0285","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.brainres.2006.07.005","article-title":"Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion","volume":"1111","author":"Zhang","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.bioadv.2022.213125_bb0290","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/bit.25289","article-title":"Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys","volume":"111","author":"Boado","year":"2014","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.bioadv.2022.213125_bb0295","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood-brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioadv.2022.213125_bb0300","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrd3187","article-title":"Coexistence of passive and carrier-mediated processes in drug transport","volume":"9","author":"Sugano","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioadv.2022.213125_bb0305","series-title":"Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors","article-title":"Physiology of the blood-brain barrier and mechanisms of transport across the BBB","author":"Lalatsa","year":"2018"},{"key":"10.1016\/j.bioadv.2022.213125_bb0310","first-page":"1","article-title":"Delivery of nanoparticles and macromolecules across the blood-brain barrier","volume":"3","author":"Nowak","year":"2020","journal-title":"Adv. Ther. (Weinh.)"},{"key":"10.1016\/j.bioadv.2022.213125_bb0315","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2015.11.024","article-title":"Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies","volume":"89","author":"Zuchero","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.bioadv.2022.213125_bb0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bioadv.2022.213125_bb0325","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neuropharm.2016.08.025","article-title":"Neuropharmacology targeting blood-brain-barrier transcytosis e perspectives for drug delivery","volume":"120","author":"Meyer","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioadv.2022.213125_bb0330","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1163","article-title":"Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice","author":"Ullman","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioadv.2022.213125_bb0335","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.addr.2007.06.008","article-title":"Endocytic mechanisms for targeted drug delivery","volume":"59","author":"Bareford","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioadv.2022.213125_bb0340","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-015-0041-1","article-title":"The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration","volume":"4","author":"Hu","year":"2015","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.bioadv.2022.213125_bb0345","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1248\/cpb.c19-00854","article-title":"Smart strategies for therapeutic agent delivery into brain across the blood\u2013brain barrier using receptor-mediated transcytosis","volume":"68","author":"Tashima","year":"2020","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.bioadv.2022.213125_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096340","article-title":"A human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by pH-dependent receptor binding","volume":"9","author":"Sade","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bioadv.2022.213125_bb0355","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/mp900235k","article-title":"Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor","volume":"7","author":"Boado","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioadv.2022.213125_bb0360","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1021\/mp1003515","article-title":"Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain","volume":"8","author":"Zhou","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioadv.2022.213125_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/DDC-120001481","article-title":"Nanoparticle technology for drug delivery across the blood-brain barrier","volume":"28","author":"Lockman","year":"2002","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.bioadv.2022.213125_bb0370","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.2147\/IJN.S120939","article-title":"Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment","volume":"11","author":"Bi","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bioadv.2022.213125_bb0375","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jconrel.2018.03.019","article-title":"A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson's disease","volume":"277","author":"Qu","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2022.213125_bb0380","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijpharm.2016.06.127","article-title":"Brain tumor-targeted therapy by systemic delivery of siRNA with transferrin receptor-mediated core-shell nanoparticles","volume":"510","author":"Wei","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioadv.2022.213125_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/238428","article-title":"Nanoparticles for brain drug delivery","volume":"2013","author":"Masserini","year":"2013","journal-title":"ISRN Biochem"},{"key":"10.1016\/j.bioadv.2022.213125_bb0390","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2022.213125_bb0395","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","article-title":"Transport of drugs across the blood-brain barrier by nanoparticles","volume":"161","author":"Wohlfart","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2022.213125_bb0400","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.1073\/pnas.1307152110","article-title":"Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor","volume":"110","author":"Wiley","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioadv.2022.213125_bb0405","series-title":"Peptide Transport and Delivery into the Central Nervous System","first-page":"39","article-title":"Structural and functional aspects of the blood-brain barrier","author":"Begley","year":"2003"},{"key":"10.1016\/j.bioadv.2022.213125_bb0410","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","article-title":"Blood-brain barrier structure and function and the challenges for CNS drug delivery","volume":"36","author":"Abbott","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bioadv.2022.213125_bb0415","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/jps.23575","article-title":"Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset","volume":"102","author":"Hoshi","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bioadv.2022.213125_bb0420","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1471-4159.2011.07208.x","article-title":"Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors","volume":"117","author":"Uchida","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioadv.2022.213125_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-8118-10-21","article-title":"A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS\/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and","volume":"10","author":"Uchida","year":"2013","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.bioadv.2022.213125_bb0430","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12987-020-00209-0","article-title":"Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human","volume":"17","author":"Zhang","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.bioadv.2022.213125_bb0435","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ddtec.2016.07.009","article-title":"Exploiting transferrin receptor for delivering drugs across the blood-brain barrier","volume":"20","author":"Paterson","year":"2016","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0440","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/312162a0","article-title":"Transferrin receptor on endothelium of brain capillaries","volume":"312","author":"Jefferies","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.bioadv.2022.213125_bb0445","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)35388-1","article-title":"Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse 1","volume":"292","author":"Lee","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioadv.2022.213125_bb0450","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2217\/imt.09.75","article-title":"Receptor-mediated therapeutic transport across the blood-brain barrier","volume":"1","author":"Wang","year":"2009","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bioadv.2022.213125_bb0455","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)35388-1","article-title":"Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse","volume":"292","author":"Lee","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioadv.2022.213125_bb0460","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s11095-007-9379-0","article-title":"Blood-brain barrier transport of therapeutics via receptor-mediation","volume":"24","author":"Jones","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioadv.2022.213125_bb0465","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s11095-008-9815-9","article-title":"Near complete rescue of experimental parkinson\u2019s disease with intravenous, non-viral GDNF gene therapy","volume":"26","author":"Zhang","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioadv.2022.213125_bb0470","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1471-4159.2001.00541.x","article-title":"Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat","volume":"79","author":"Moos","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioadv.2022.213125_bb0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioadv.2022.213125_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2019.101665","article-title":"Targeting the transferrin receptor for brain drug delivery","volume":"181","author":"Johnsen","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-020-00214-1","article-title":"SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-\u03b2 antibody in a mouse model of Alzheimer's disease","volume":"9","author":"Gustavsson","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.bioadv.2022.213125_bb0490","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.neuroimage.2018.10.011","article-title":"High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain","volume":"184","author":"Fang","year":"2019","journal-title":"NeuroImage"},{"key":"10.1016\/j.bioadv.2022.213125_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-17358-2","article-title":"Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-\u03b2","volume":"7","author":"Sehlin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioadv.2022.213125_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms10759","article-title":"Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease","volume":"7","author":"Sehlin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioadv.2022.213125_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3009835","article-title":"Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates","volume":"6","author":"Yu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioadv.2022.213125_bb0510","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1163","article-title":"Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice","author":"Ullman","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioadv.2022.213125_bb0515","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1359","article-title":"Brain delivery of therapeutic proteins using an fc fragment blood-brain barrier transport vehicle in mice and monkeys","volume":"12","author":"Kariolis","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioadv.2022.213125_bb0520","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev.pharmtox.47.120505.105237","article-title":"Drug targeting to the brain","volume":"47","author":"De Boer","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0525","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioadv.2022.213125_bb0530","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jbiotec.2010.01.011","article-title":"Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein","volume":"146","author":"Boado","year":"2010","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0535","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1007592720793","article-title":"Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor","volume":"17","author":"Coloma","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioadv.2022.213125_bb0540","doi-asserted-by":"crossref","unstructured":"G. A. Werther et al Localization of Insulin-Like Growth Factor-I mRNA in Rat Brain by in Situ Hybridization \u2014 Relationship to IGF-I Receptors. 773\u2013778.","DOI":"10.1210\/mend-4-5-773"},{"key":"10.1016\/j.bioadv.2022.213125_bb0545","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1023\/A:1016244500596","article-title":"Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro.Pdf","volume":"12","author":"Pardridge","year":"1995","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioadv.2022.213125_bb0550","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/bit.21120","article-title":"Humanization of anti-human insulin receptor antibody for drug targeting across the human blood\u2013brain barrier","volume":"96","author":"Boado","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.bioadv.2022.213125_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0849-8","article-title":"Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type i after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial","volume":"13","author":"Giugliani","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bioadv.2022.213125_bb0560","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/bit.21602","article-title":"Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier","volume":"99","author":"Boado","year":"2008","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.bioadv.2022.213125_bb0565","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.brainresbull.2009.12.008","article-title":"Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo","volume":"81","author":"Huang","year":"2010","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bioadv.2022.213125_bb0570","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1073\/pnas.0702170104","article-title":"Targeted delivery of proteins across the blood-brain barrier","volume":"104","author":"Spencer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioadv.2022.213125_bb0575","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0896-6273(93)90070-8","article-title":"Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions","volume":"11","author":"William Rebeck","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.bioadv.2022.213125_bb0580","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/a08f47c0-6236-4116-821f-fa68c6b9a182","article-title":"A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier","volume":"3","author":"Karkan","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.bioadv.2022.213125_bb0585","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1242\/jcs.01381","article-title":"Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier","volume":"117","author":"Pan","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bioadv.2022.213125_bb0590","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nature05901","article-title":"Transvascular delivery of small interfering RNA to the central nervous system","volume":"448","author":"Kumar","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bioadv.2022.213125_bb0595","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1021\/bc3005123","article-title":"IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys","volume":"24","author":"Boado","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioadv.2022.213125_bb0600","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.molimm.2015.07.001","article-title":"Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1","volume":"67","author":"Leoh","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0605","doi-asserted-by":"crossref","first-page":"12754","DOI":"10.1073\/pnas.221450098","article-title":"Brain-specific expression of an exogenous gene after i.v. administration","volume":"98","author":"Shi","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioadv.2022.213125_bb0610","series-title":"Gene Therapy Protocols","first-page":"205","article-title":"Evaluation of promoters for use in tissue-specific gene delivery","author":"Zheng","year":"2008"},{"key":"10.1016\/j.bioadv.2022.213125_bb0615","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1126\/science.285.5433.1569","article-title":"In vivo protein transduction: delivery of a biologically active protein into the mouse","volume":"285","author":"Schwarze","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bioadv.2022.213125_bb0620","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF01190839","article-title":"Ultracytochemical characterization of anionic sites in the wall of brain capillaries","volume":"18","author":"Vorbrodt","year":"1989","journal-title":"J. Neurocytol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0625","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1021\/bi048080x","article-title":"An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells \u2020","volume":"44","author":"Sauer","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioadv.2022.213125_bb0630","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2165\/00003088-200544060-00002","article-title":"Clinical pharmacokinetics of atomoxetine","volume":"44","author":"Sauer","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bioadv.2022.213125_bb0635","doi-asserted-by":"crossref","first-page":"17867","DOI":"10.1073\/pnas.0408191101","article-title":"Tumor imaging by means of proteolytic activation of cell-penetrating peptides","volume":"101","author":"Jiang","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioadv.2022.213125_bb0640","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuroimage.2005.06.007","article-title":"Crossing the blood \u2013 brain barrier: a potential application of myristoylated polyarginine for in vivo neuroimaging","volume":"28","author":"Pham","year":"2005","journal-title":"NeuroImage"},{"key":"10.1016\/j.bioadv.2022.213125_bb0645","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ddtec.2016.07.007","article-title":"Ultrasound-mediated drug delivery to the brain: principles, progress and prospects","volume":"20","author":"Dasgupta","year":"2016","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0650","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/adfm.201401199","article-title":"Theranostic USPIO-loaded microbubbles for mediating and monitoring blood-brain barrier permeation","volume":"25","author":"Lammers","year":"2015","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.bioadv.2022.213125_bb0655","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.biomaterials.2011.09.096","article-title":"Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment","volume":"33","author":"Ting","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioadv.2022.213125_bb0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0002175","article-title":"Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models","volume":"3","author":"Raymond","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.bioadv.2022.213125_bb0665","doi-asserted-by":"crossref","first-page":"371","DOI":"10.5405\/jmbe.871","article-title":"Diagnostic ultrasound: past, present, and future","volume":"31","author":"Shung","year":"2011","journal-title":"J. Med. Biol. Eng."},{"key":"10.1016\/j.bioadv.2022.213125_bb0670","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.7150\/thno.4306","article-title":"Advances in ultrasound mediated gene therapy using microbubble contrast agents","volume":"2","author":"Sirsi","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.bioadv.2022.213125_bb0675","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1088\/0031-9155\/54\/6\/R01","article-title":"Ultrasound contrast microbubbles in imaging and therapy: physical principles and engineering","volume":"54","author":"Qin","year":"2009","journal-title":"Phys. Med. Biol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0680","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.bbrc.2005.12.112","article-title":"Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound","volume":"340","author":"Kinoshita","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioadv.2022.213125_bb0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abj4011","article-title":"MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases","volume":"13","author":"Meng","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioadv.2022.213125_bb0690","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1179\/175889709X446507","article-title":"Microbubble compositions, properties and biomedical applications","volume":"1","author":"Sirsi","year":"2009","journal-title":"Bubble Sci. Eng. Technol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0695","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.mri.2016.11.023","article-title":"Pharmacokinetic analysis and drug delivery efficiency of the focused ultrasound-induced blood-brain barrier opening in non-human primates","volume":"37","author":"Samiotaki","year":"2017","journal-title":"Magn. Reson. Imaging"},{"key":"10.1016\/j.bioadv.2022.213125_bb0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0166061","article-title":"Effects on P-glycoprotein expression after blood-brain barrier disruption using focused ultrasound and microbubbles","volume":"12","author":"Aryal","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bioadv.2022.213125_bb0705","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/2017.11.FOCUS17620","article-title":"A review of potential applications of MR-guided focused ultrasound for targeting brain tumor therapy","volume":"44","author":"Lamsam","year":"2018","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.bioadv.2022.213125_bb0710","doi-asserted-by":"crossref","first-page":"11719","DOI":"10.1073\/pnas.0604318103","article-title":"Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption","volume":"103","author":"Kinoshita","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioadv.2022.213125_bb0715","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/A:1007049806660","article-title":"Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications","volume":"20","author":"Rapoport","year":"2000","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0720","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0169-409X(98)00082-9","article-title":"Blood-brain barrier permeability to small and large molecules","volume":"36","author":"Cornford","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioadv.2022.213125_bb0725","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bioadv.2022.213125_bb0730","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JAD-1998-1102","article-title":"Delivery of nerve growth factor to the brain via the olfactory pathway","volume":"1","author":"Chen","year":"1998","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bioadv.2022.213125_bb0735","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/10717549709051878","article-title":"Delivery of 125I-NGF to the brain via the olfactory route","volume":"4","author":"Frey","year":"1997","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bioadv.2022.213125_bb0740","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3109\/10717544.2014.920431","article-title":"Nasal-nanotechnology: revolution for efficient therapeutics delivery","volume":"23","author":"Kumar","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bioadv.2022.213125_bb0745","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","article-title":"Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules","volume":"88","author":"Fortuna","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bioadv.2022.213125_bb0750","first-page":"1","article-title":"Imaging of intranasal drug delivery to the brain","volume":"10","author":"Veronesi","year":"2020","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioadv.2022.213125_bb0755","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2017.09.001","article-title":"Progress in brain targeting drug delivery system by nasal route","volume":"268","author":"Khan","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2022.213125_bb0760","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4081\/1761","article-title":"Drug delivery to the central nervous system","volume":"54","author":"Imberti","year":"2010","journal-title":"Eur. J. Histochem."},{"key":"10.1016\/j.bioadv.2022.213125_bb0765","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1124\/jpet.301.3.878","article-title":"Positron emission tomography shows that intrathecal leptin reaches the hypothalamus in baboons","volume":"301","author":"McCarthy","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioadv.2022.213125_bb0770","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2377-9-S1-S3","article-title":"Characteristics of compounds that cross the blood-brain barrier","volume":"9","author":"Banks","year":"2009","journal-title":"BMC Neurol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0775","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0896-6273(02)01054-1","article-title":"Drug and gene delivery to the brain: the vascular route","volume":"36","author":"Pardridge","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.bioadv.2022.213125_bb0780","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s13311-017-0520-4","article-title":"Convection-enhanced delivery","volume":"14","author":"Mehta","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"214","key":"10.1016\/j.bioadv.2022.213125_bb0785","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1126\/science.7313698","article-title":"Site-specific, sustained release of drugs to the brain","volume":"1979","author":"Bodor","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.bioadv.2022.213125_bb0790","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev-pharmtox-010814-124852","article-title":"Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier","volume":"55","author":"Lajoie","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0795","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","article-title":"Convection-enhanced delivery of macromolecules in the brain","volume":"91","author":"Hunt Bobo","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioadv.2022.213125_bb0800","first-page":"1","article-title":"Towards selective CNS PET imaging of the 5-HT7 receptor system: past, present and future","volume":"172","author":"L\u2019Estrade","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioadv.2022.213125_bb0805","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/10611860903548354","article-title":"Biopharmaceutical drug targeting to the brain","volume":"18","author":"Pardridge","year":"2010","journal-title":"J. Drug Target."},{"key":"10.1016\/j.bioadv.2022.213125_bb0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12987-021-00257-0","article-title":"Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size","volume":"18","author":"Faresj\u00f6","year":"2021","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.bioadv.2022.213125_bb0815","first-page":"1154","article-title":"PET and drug research and development","volume":"40","author":"Fowler","year":"1999","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioadv.2022.213125_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2018.06.021","article-title":"Pretargeting in nuclear imaging and radionuclide therapy: improving efficacy of theranostics and nanomedicines","volume":"179","author":"St\u00e9en","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioadv.2022.213125_bb0825","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1021\/acs.bioconjchem.6b00235","article-title":"Pretargeted PET imaging using a site-specifically labeled immunoconjugate","volume":"27","author":"Cook","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioadv.2022.213125_bb0830","doi-asserted-by":"crossref","DOI":"10.1039\/D1SC02789A","article-title":"Direct aromatic 18F-labeling of highly reactive tetrazines for pretargeted bioorthogonal PET imaging","author":"Garc\u00eda-V\u00e1zquez","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioadv.2022.213125_bb0835","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1021\/acsptsci.1c00007","article-title":"Lipophilicity and click reactivity determine the performance of bioorthogonal tetrazine tools in pretargeted in vivo chemistry","volume":"4","author":"St\u00e9en","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bioadv.2022.213125_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2018.06.021","article-title":"Pretargeting in nuclear imaging and radionuclide therapy: improving efficacy of theranostics and nanomedicines","volume":"179","author":"St\u00e9en","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioadv.2022.213125_bb0845","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cbpa.2014.07.023","article-title":"Pretargeted imaging using bioorthogonal chemistry in mice","volume":"21","author":"Rossin","year":"2014","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bioadv.2022.213125_bb0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics11080376","article-title":"Beyond the barrier: targeted radionuclide therapy in brain tumors and metastases","volume":"11","author":"Puttemans","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioadv.2022.213125_bb0855","doi-asserted-by":"crossref","first-page":"13272","DOI":"10.1096\/fj.202000610RR","article-title":"Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle","volume":"34","author":"Sehlin","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.bioadv.2022.213125_bb0860","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","article-title":"CSF, blood-brain barrier, and brain drug delivery","volume":"13","author":"Pardridge","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.bioadv.2022.213125_bb0865","series-title":"Nanostructured Biomaterials for Ovrecoming Biological Barriers","first-page":"329","article-title":"Chapter 7.1. nanostructures overcoming the blood-brain barrier: physiological considerations and mechanistic issues","author":"Lalatsa","year":"2012"},{"key":"10.1016\/j.bioadv.2022.213125_bb0870","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jconrel.2021.03.029","article-title":"BBB-crossing adeno-associated virus vector: an excellent gene delivery tool for CNS disease treatment","volume":"333","author":"Chen","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2022.213125_bb0875","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.msec.2017.12.029","article-title":"Targeted transport of nanocarriers into brain for theranosis with rabies virus glycoprotein-derived peptide","volume":"87","author":"Fu","year":"2018","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.bioadv.2022.213125_bb0880","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.biotechadv.2015.02.004","article-title":"BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS","volume":"33","author":"Peluffo","year":"2015","journal-title":"Biotechnol. Adv."}],"container-title":["Biomaterials Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950822004022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950822004022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:47:21Z","timestamp":1757425641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772950822004022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":176,"alternative-id":["S2772950822004022"],"URL":"https:\/\/doi.org\/10.1016\/j.bioadv.2022.213125","relation":{},"ISSN":["2772-9508"],"issn-type":[{"value":"2772-9508","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy","name":"articletitle","label":"Article Title"},{"value":"Biomaterials Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioadv.2022.213125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"213125"}}